Previous Article | Next Article ![]()
Journal of Clinical Microbiology, March 2000, p. 1175-1179, Vol. 38, No. 3
Centre for Infectious Diseases and
Microbiology, Institute of Clinical Pathology and Medical Research,
Westmead, New South Wales, Australia
Received 1 September 1999/Returned for modification 11 November
1999/Accepted 9 December 1999
There is good evidence that the organism currently known as
Ureaplasma urealyticum should be divided into two
species Evidence has been presented that the
species currently known as Ureaplasma urealyticum should be
separated into two new species, namely, U. parvum
(previously U. urealyticum biovar 1) and U. urealyticum (previously U. urealyticum biovar 2)
(9). Ureaplasmas are commensals in the genital tract,
recognized causes of disease (15), and suspected
contributors to a number of other pathological conditions
(1). Because they are commonly found in healthy people,
their pathogenic role can be difficult to prove (10, 18).
The majority of human ureaplasma isolates belong to the proposed new
species U. parvum (1, 3, 5, 7, 8), which includes
serovars 1, 3, 6, and 14. U. urealyticum (biovar 2) is
isolated less often but is not uncommon. Some ureaplasma serovars have
been associated with disease syndromes more commonly than with normal
flora (19), but data are limited because of difficulties
with conventional serotyping methods. Rapid molecular methods for
identification of species and subtypes would be of great value in
studies of the epidemiology and pathogenesis of infections with
U. parvum and U. urealyticum (8).
Recently, PCR-based methods have been used successfully to distinguish
the two Ureaplasma species (biovars), but there is a need to
improve their specificity and sensitivity (2, 8). Target
sequences of the 16S rRNA gene and 16S rRNA-23S rRNA intergenic spacer
regions (6, 12), the urease gene subunits (2,
11), and the 5' ends of the multiple-banded antigen (MBA) genes
(8, 16, 17) have all been used in PCR-based assays to
differentiate U. parvum from U. urealyticum.
Previously, we have sequenced portions of these genes from all 14 Ureaplasma serovars (9) and described PCR-based
assays for the identification of U. parvum and U. urealyticum and the subtyping of U. parvum
(8). In the present study, we evaluated the specificity of a
large range of primers and used a small subset to develop an algorithm
for the detection, species identification, and subtyping of
Ureaplasma species.
Bacterial strains.
Two sets of reference strains of all 14 serovars of U. urealyticum (including biovars 1 and 2, referred to hereafter as U. parvum and U. urealyticum, respectively) were used as previously described
(8, 9). These included one set obtained directly from the
American Type Culture Collection (ATCC reference strains) and another
kindly provided by H. L. Watson, Department of Microbiology, University of Alabama at Birmingham (UAB reference strains). Additional reference strains from the ATCC were used to test the specificity of
primers: Mycoplasma pneumoniae strains M129 (ATCC 29342) and FH (ATCC 15531), Mycoplasma genitalium (ATCC 33530),
Mycoplasma fermentans (ATCC 19989), Mycoplasma
hyorhinis (ATCC 17981), and Acholeplasma laidlawii
(ATCC 23206). Mycoplasma hominis isolates were grown from
clinical specimens on A7 agar in our laboratory and identified by
colonial morphology and partial sequencing of the 16S rRNA gene and the
16S rRNA-23S rRNA gene spacer regions.
Clinical isolates and specimens.
A total of 78 Ureaplasma isolates obtained from vaginal swabs of pregnant
women and recently cultured in our laboratory and 185 vaginal swabs
obtained from pregnant women and women attending a sexually transmitted
disease clinic and in which Ureaplasma species had been
previously detected (8) were used in this study.
Oligonucleotide primers.
The 29 individual primers used in
this study to amplify portions of three genes of all 14 serovars are
shown in Table 1. They include 4 primers
that have been previously described (12, 16, 17) and 25 new
primers designed by us. The nomenclature of our primers is based on
specificity (e.g., UU and UP for U. urealyticum and U. parvum, respectively), gene target (e.g., UM for the MBA genes),
the direction of the sequence (S, sense; A, antisense), and the
numbered base position at which the primer sequence starts
(9).
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Species Identification and Subtyping of
Ureaplasma parvum and Ureaplasma urealyticum
Using PCR-Based Assays
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
U. parvum (previously U. urealyticum
biovar 1) and U. urealyticum (previously U. urealyticum biovar 2). In this study, we designed a series of
primers, targeting the 16S rRNA gene and 16S rRNA-23S rRNA intergenic
spacer regions, the urease gene subunits, and the 5' ends of the
multiple-banded antigen (MBA) genes, to identify and subtype these
Ureaplasma species. All of the species-specific primer
pairs could distinguish the two species, but only subtype-specific primer pairs targeting the MBA genes could distinguish subtypes within
each species. U. parvum was separated into three subtypes, represented by serovars 1, 3/14, and 6. U. urealyticum was
also separated into three subtypes by PCR and/or direct sequencing. Subtype 1 consisted of serovars 2, 5, 8, and 9; subtype 2 contained serovars 4, 10, 12, and 13; and subtype 3 contained serovars 7 and 11. A selection of primer pairs was used to identify and subtype 78 clinical ureaplasma isolates from vaginal swabs of pregnant women and
to identify and subtype ureaplasmas directly in 185 vaginal swabs in
which they had been previously detected. U. parvum was
identified in 228 (87%) of 263 isolates or specimens, and U. urealyticum was identified in 50 (19%) (both were present in 6%). Serovars 3/14 (48%) and 1 (43%) were most common among U. parvum isolates, and subtypes 2 (62%) and 1 (34%) were most
common among U. urealyticum isolates. This new PCR-based
typing system will facilitate future studies of the relationship
between individual Ureaplasma species or subtypes and human disease.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Primers targeting the sequences of three different genes
or regions
DNA preparation and PCRs. DNA preparation and PCR were performed as previously described (8, 9). In each reaction, positive and negative controls were processed in parallel with the tested samples to detect false-negative results or contamination. Melting temperature values are shown in Table 1. The annealing temperature was 58°C for all primer pairs except UPS2-UPA2, UUS2-UUA2, UMS-170-UMA263, and UMS-61-UMA263, for which the annealing temperature was 55°C.
Subtyping of U. urealyticum by direct
sequencing.
We previously showed (9) that the 10 serovars of the new species U. urealyticum could be divided
into three subtypes based on sequence differences in amplified
fragments of the 5' ends of the MBA genes at six positions between
112 and 251. With primers UMS-170 and UMA263, amplified fragments of
reference serovars, clinical isolates, and specimens were sequenced by
use of an ABI 373A sequencing machine with Applied Biosystems
Taq DyeDeoxy Terminator Cycle-Sequencing Ready Reaction Kits
according to the manufacturer's instructions. All of the U. urealyticum isolates and specimens were sequenced with primer
UMS-170; some were also sequenced with primer UMA263 to confirm the results.
Algorithm for identification and subtyping of U. parvum and U. urealyticum.
In order to develop a
practical identification and subtyping scheme, we designed an algorithm
(Fig. 1) for clinical use and then
applied it to all known Ureaplasma serovars in the ATCC and UAB reference sets and to clinical isolates and clinical specimens.
|
| |
RESULTS |
|---|
|
|
|---|
PCRs. No amplification occurred when DNA extracted from Mycoplasma or Acholeplasma species was tested with any of 17 primer pairs. Five primer pairs (UPS1-UPA, UPS1-UPA1, UPS-UPSA, UPS2-UPA2, and UMS-57-UMA222) were specific for and amplified all 4 serovars of U. parvum, and four (U8-UUA, UUS-UUSA, UUS2-UUA2, and UMS-61-UMA263) were specific for and amplified all 10 serovars of U. urealyticum.
Serovars of U. parvum could be identified with new primer pairs as follows: UMS-83-UMA269' amplified only serovar 1; UMS-125-UMA269 amplified only serovar 3 or 14; and UMS-54-UMA269' amplified only serovar 6. The three subtypes of U. urealyticum could be identified with new primer pairs as follows: UMS-61-UMA219 amplified subtypes 1 and 2 only; UMS-61-UMA219' amplified subtype 3 only; UMS-112-UMA194 amplified subtypes 1 and 3 only; and UMS-112'-UMA194' amplified subtype 2 only. Nine primer pairs were used in combination to identify Ureaplasma species and serovars or subtypes as shown in Fig. 1.Specificity of U. parvum and U. urealyticum identification and subtyping primers. All the ATCC and UAB reference strains of U. parvum and U. urealyticum were correctly identified with the species- and subtype-specific primers as shown in the algorithm (Fig. 1).
U. parvum and U. urealyticum identification
and subtyping results for clinical isolates and clinical
specimens.
Of the 78 clinical isolates, 62 (79.5%) were
identified as U. parvum, 15 (19.2%) were identified as
U. urealyticum, and 1 (1.3%) was mixed. Of 185 vaginal
swabs that had been shown previously to contain Ureaplasma
species, 151 (81.6%) contained U. parvum only, 20 (10.8%)
contained U. urealyticum only, and 14 (7.6%) contained
both. Results of subtyping of clinical isolates and Ureaplasma species in vaginal swabs are shown in Table
2.
|
| |
DISCUSSION |
|---|
|
|
|---|
In the past, U. urealyticum was divided into two biovars by various phenotypic and genetic methods (9). Recently, we reported new data supporting the proposal that these two biovars be designated separate species, namely, U. parvum (previously U. urealyticum biovar 1) and U. urealyticum (previously U. urealyticum biovar 2) (9). Several primer sets have been described for the identification of biovars of the old species U. urealyticum (or the new species U. parvum and U. urealyticum). However, they were not based on the sequences of all 14 serovars (2, 12, 13, 16, 17), and some lacked specificity or the ability to detect all serovars (2, 12). Better PCR-based methods for both identification and subtyping are needed to facilitate studies of the relationship between Ureaplasma species or subtype and disease (4).
Many of the primer targets used in this study were based on our previous observation that the heterogeneity of the intergenic spacer regions is greater than that within the genes (9). We believed that primers based on these regions would be more discriminatory for the identification and subtyping of Ureaplasma species (9). These included primers UPSA-UUSA (16S rRNA-23S rRNA gene spacer regions); UPS2-UPA2 and UUS2-UUA2 (ureA-ureB and ureB-ureC gene spacer regions, respectively); and UMS-57, UMS-61, UMS-83, UMS-54, UMS-112, and UMS-112' (upstream of the MBA genes) (Table 1).
Differences between the two proposed new species in the 16S rRNA genes have been described previously and used to design biovar-specific (or species-specific) primers (12). The primer pair U8-P6, designed to amplify U. urealyticum (biovar 2), also amplified DNA from M. pneumoniae (12), which is found not infrequently in the genital tract (14). We designed a new primer, UUA, which was paired with U8. This pair was specific for U. urealyticum (biovar 2) and did not amplify DNA from two M. pneumoniae ATCC strains or other Mycoplasma species tested. Two new U. parvum (biovar 1)-specific primer pairs, UPS1-UPA and UPS-UPA, also based on the 16S rRNA gene, did not amplify DNA from either U. urealyticum (biovar 2) or the Mycoplasma species tested.
The 16S rRNA and 23S rRNA gene spacer regions are normally
continuous with but more heterogeneous than the 16S rRNA genes (6, 9). Primers spanning these regions
UPS-UPSA for
U. parvum (biovar 1) and UUS-UUSA for U. urealyticum (biovar 2)
were specific for all serovars
within the corresponding species (biovar) for both ATCC and UAB
reference strains.
Primers based on urease gene sequences and used to differentiate U. parvum and U. urealyticum have been described previously (2, 13). We designed two additional species-specific primer sets, UPS2-UPA2 (U. parvum specific) and UUS2-UUA2 (U. urealyticum specific), targeting the ureA-ureB and ureB-ureC gene spacer regions, respectively. They were specific for all serovars within the corresponding species (biovar) for both ATCC and UAB reference strains.
The MBA genes contain both species- and serovar-defining regions (19, 20). Several primer sets based on MBA sequences have been described previously for differentiating U. parvum and U. urealyticum (9, 16, 17). To improve sensitivity and specificity and to provide more choice, we designed additional species-specific primers based on our sequencing results. The primer pair UMS-57-UMA222 was specific for U. parvum, and UMS-61-UMA263 was specific for U. urealyticum.
Although the 5' ends of the MBA genes are highly conserved among the 10 serovars of U. urealyticum, we were able to distinguish three subtypes based on sequence data (9). There is more sequence variation in the 5' ends of the MBA genes of the four serovars of U. parvum, which allow them to be separated into three groups. Primer pairs with specificity for individual serovars or subtypes of U. parvum and U. urealyticum were used in combination and supplemented, when necessary, by sequencing of UMS-170-UMA 263 amplicons to characterize human ureaplasmas, as shown in Fig. 1.
Having confirmed the sensitivity and specificity of the new primer pairs, we designed an algorithm (Fig. 1) for the identification and subtyping of U. parvum and U. urealyticum, using a selection of the most suitable primers. Its utility was evaluated with ATCC and UAB reference strains, stored clinical isolates, and Ureaplasma-positive clinical specimens. The results suggested that the algorithm would be particularly suitable for use in epidemiological studies. Identification and subtyping of clinical isolates and specimens confirmed the previous finding that U. parvum is found much more commonly (87% of isolates or specimens overall) than U. urealyticum (19%) among vaginal flora (3). Both Ureaplasma species were detected in 1 clinical isolate (1%) and 14 vaginal swabs (8%) (6% overall). Among the U. parvum strains detected, serovars 3/14 (48%) and 1 (43%) were found more commonly than serovar 6 (23%); 8% of isolates and 16% of vaginal swabs (14% overall) contained two or more subtypes. U. urealyticum subtypes 1 (34%) and 2 (62%) were found more commonly than subtype 3 (6%). Only one clinical isolate contained mixed U. urealyticum subtypes.
In summary, we have designed a series of new primer pairs based on previously reported sequences of three important ureaplasma genes and adjoining regions and modified some previously published primers to improve their sensitivity and specificity. Our initial evaluation of the algorithm for the identification and subtyping of U. parvum and U. urealyticum, using a selected set of primers with ATCC and UAB reference strains, clinical isolates, and clinical specimens, confirmed their specificity and sensitivity. Further evaluation of their sensitivity for direct examination of clinical specimens is required. However, we believe that, in the future, they will assist in studies of the epidemiology, pathogenicity, and clinical significance of Ureaplasma species in humans and will provide significant advantages over conventional serotyping methods.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Darcy Rd., Westmead, New South Wales, 2145 Australia. Phone: (612) 9845 6255. Fax: (612) 9893 8659. E-mail: lyng{at}icpmr.wsahs.nsw.gov.au.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Abele-Horn, M., C. Wolff, P. Dressel, F. Pfaff, and A. Zimmermann. 1997. Association of Ureaplasma urealyticum biovars with clinical outcome for neonates, obstetric patients, and gynecological patients with pelvic inflammatory disease. J. Clin. Microbiol. 35:1199-1202[Abstract]. |
| 2. | Blanchard, A. 1990. Ureaplasma urealyticum urease genes: use of a UGA tryptophan codon. Mol. Microbiol. 4:669-676[CrossRef][Medline]. |
| 3. |
Cheng, X.,
A. Naessens, and S. Lauwers.
1994.
Identification of serotype 1-, 3-, and 6-specific antigens of Ureaplasma urealyticum by using monoclonal antibodies.
J. Clin. Microbiol.
32:1060-1062 |
| 4. | Cunliffe, N. A., S. Fergusson, F. Davidson, A. Lyon, and P. W. Ross. 1996. Comparison of culture with the polymerase chain reaction for detection of Ureaplasma urealyticum in endotracheal aspirates of preterm infants. J. Med. Microbiol. 45:27-30[Abstract]. |
| 5. | Grattard, F., B. Pozzetto, B. B. de Barbeyrac, H. Renaudin, M. Clerc, O. G. Gaudin, and C. Bebear. 1995. Arbitrarily-primed PCR confirms the differentiation of strains of Ureaplasma urealyticum into two biovars. Mol. Cell. Probes 9:383-389[CrossRef][Medline]. |
| 6. | Harasawa, R., H. Mizusawa, K. Nozawa, T. Nakagawa, K. Asada, and I. Kato. 1993. Detection and tentative identification of dominant Mycoplasma species in cell cultures by restriction analysis of the 16s-23s rRNA intergenic spacer regions. Res. Microbiol. 144:489-493[Medline]. |
| 7. | Kong, F., X. Zhu, and J. Zhou. 1996. Grouping and typing of Ureaplasma urealyticum. Chung Hua I Hsueh Tsa Chih 76:138-140. |
| 8. |
Kong, F.,
X. Zhu,
W. Wang,
X. Zhou,
S. Gordon, and G. L. Gilbert.
1999.
Comparative analysis and serovar-specific identification of multiple-banded antigen genes of Ureaplasma urealyticum biovar 1.
J. Clin. Microbiol.
37:538-543 |
| 9. |
Kong, F.,
G. James,
Z. Ma,
S. Gordon,
B. Wang, and G. L. Gilbert.
1999.
Phylogenetic analysis of Ureaplasma urealyticum support for the establishment of a new species, Ureaplasma parvum.
Int. J. Syst. Bacteriol.
49:1879-1889 |
| 10. | Ollikainen, J., T. Heiskanen-Kosma, M. Korppi, M. L. Katila, and K. Heinonen. 1998. Clinical relevance of Ureaplasma urealyticum colonization in preterm infants. Acta Paediatr. 87:1075-1078[CrossRef][Medline]. |
| 11. |
Povlsen, K.,
J. S. Jensen, and I. Lind.
1998.
Detection of Ureaplasma urealyticum by PCR and biovar determination by liquid hybridization.
J. Clin. Microbiol.
36:3211-3216 |
| 12. |
Robertson, J. A.,
A. Vekris,
C. Bebear, and G. W. Stemke.
1993.
Polymerase chain reaction using 16S rRNA gene sequences distinguishes the two biovars of Ureaplasma urealyticum.
J. Clin. Microbiol.
31:824-830 |
| 13. | Ruifu, Y., Z. Minli, Z. Guo, and X. Wang. 1997. Biovar diversity is reflected by variations of genes encoding urease of Ureaplasma urealyticum. Microbiol. Immunol. 41:625-627[Medline]. |
| 14. |
Sharma, S.,
R. Brousseau, and S. Kasatiya.
1998.
Detection and confirmation of Mycoplasma pneumoniae in urogenital specimens by PCR.
J. Clin. Microbiol.
36:277-280 |
| 15. | Taylor-Robinson, D., and P. M. Furr. 1997. Genital Mycoplasma infections. Wien. Klin. Wochenschr. 109:578-583[Medline]. |
| 16. |
Teng, L. J.,
X. Zheng,
J. I. Glass,
H. L. Watson,
J. Tsai, and G. H. Cassell.
1994.
Ureaplasma urealyticum biovar specificity and diversity are encoded in multiple-banded antigen gene.
J. Clin. Microbiol.
32:1464-1469 |
| 17. | Teng, L. J., S. W. Ho, H. N. Ho, S. J. Liaw, H. C. Lai, and K. T. Luh. 1995. Rapid detection and biovar differentiation of Ureaplasma urealyticum in clinical specimens by PCR. J. Form. Med. Assoc. 94:396-400. |
| 18. | Tully, J. G. 1993. Current status of the mollicute flora of humans. Clin. Infect. Dis. 17(Suppl. 1):S2-S9. |
| 19. |
Zheng, X.,
H. L. Watson,
K. B. Waites, and G. H. Cassell.
1992.
Serotype diversity and antigen variation among invasive isolates of Ureaplasma urealyticum from neonates.
Infect. Immun.
60:3472-3474 |
| 20. | Zheng, X., L. J. Teng, H. L. Watson, J. I. Glass, A. Blanchard, and G. H. Cassell. 1995. Small repeating units within the Ureaplasma urealyticum MB antigen gene encode serovar specificity and are associated with antigen size variation. Infect. Immun. 63:891-898[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|